![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | GFPT2 | Human | (-)-epigallocatechin 3-gallate | multiple interactions | EXP | | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GFPT2 mRNA | CTD | PMID:22079256 | GFPT2 | Human | 1,2-dimethylhydrazine | decreases expression | ISO | Gfpt2 (Mus musculus) | 6480464 | 1 and 2-Dimethylhydrazine results in decreased expression of GFPT2 mRNA | CTD | PMID:22206623 | GFPT2 | Human | 1-naphthyl isothiocyanate | increases expression | ISO | Gfpt2 (Rattus norvegicus) | 6480464 | 1-Naphthylisothiocyanate results in increased expression of GFPT2 mRNA | CTD | PMID:30723492 | GFPT2 | Human | 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of GFPT2 mRNA | CTD | PMID:31614463 | GFPT2 | Human | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | EXP | | 6480464 | Tetrachlorodibenzodioxin affects the expression of GFPT2 mRNA | CTD | PMID:22298810 | GFPT2 | Human | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | Gfpt2 (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin results in increased expression of GFPT2 mRNA | CTD | PMID:33387578 | GFPT2 | Human | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | Gfpt2 (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of GFPT2 mRNA | CTD | PMID:34747641 | GFPT2 | Human | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | Gfpt2 (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin results in increased expression of GFPT2 mRNA | CTD | PMID:27562557 | GFPT2 | Human | 2,4-dibromophenyl 2,4,5-tribromophenyl ether | affects expression | ISO | Gfpt2 (Mus musculus) | 6480464 | 2 more ... | CTD | PMID:38648751 | GFPT2 | Human | 2,6-di-tert-butyl-4-methylphenol | increases expression | ISO | Gfpt2 (Mus musculus) | 6480464 | Butylated Hydroxytoluene results in increased expression of GFPT2 mRNA | CTD | PMID:19925653 | GFPT2 | Human | 2-hydroxypropanoic acid | decreases expression | EXP | | 6480464 | Lactic Acid results in decreased expression of GFPT2 mRNA | CTD | PMID:30851411 | GFPT2 | Human | 2-palmitoylglycerol | increases expression | EXP | | 6480464 | 2-palmitoylglycerol results in increased expression of GFPT2 mRNA | CTD | PMID:37199045 | GFPT2 | Human | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | EXP | | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of GFPT2 mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of GFPT2 mRNA | CTD | PMID:28628672 | GFPT2 | Human | 4,4'-sulfonyldiphenol | multiple interactions | EXP | | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of GFPT2 mRNA | CTD | PMID:28628672 | GFPT2 | Human | 4,4'-sulfonyldiphenol | increases expression | ISO | Gfpt2 (Mus musculus) | 6480464 | bisphenol S results in increased expression of GFPT2 mRNA | CTD | PMID:30951980 | GFPT2 | Human | 4-hydroxyphenyl retinamide | increases expression | ISO | Gfpt2 (Mus musculus) | 6480464 | Fenretinide results in increased expression of GFPT2 mRNA | CTD | PMID:28973697 | GFPT2 | Human | 6-propyl-2-thiouracil | decreases expression | ISO | Gfpt2 (Rattus norvegicus) | 6480464 | Propylthiouracil results in decreased expression of GFPT2 mRNA | CTD | PMID:25825206 | GFPT2 | Human | 8-Br-cAMP | increases expression | EXP | | 6480464 | 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GFPT2 mRNA | CTD | PMID:20147733 | GFPT2 | Human | acrylamide | affects expression | ISO | Gfpt2 (Rattus norvegicus) | 6480464 | Acrylamide affects the expression of GFPT2 mRNA | CTD | PMID:28959563 | GFPT2 | Human | acrylamide | increases expression | EXP | | 6480464 | Acrylamide results in increased expression of GFPT2 mRNA | CTD | PMID:32763439 | GFPT2 | Human | acrylamide | increases expression | ISO | Gfpt2 (Mus musculus) | 6480464 | Acrylamide results in increased expression of GFPT2 mRNA | CTD | PMID:30807115 | GFPT2 | Human | aflatoxin B1 | increases expression | EXP | | 6480464 | Aflatoxin B1 results in increased expression of GFPT2 mRNA | CTD | PMID:22100608 | GFPT2 | Human | aflatoxin B1 | increases expression | ISO | Gfpt2 (Rattus norvegicus) | 6480464 | Aflatoxin B1 results in increased expression of GFPT2 mRNA | CTD | PMID:25378103 | GFPT2 | Human | all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of GFPT2 mRNA | CTD | PMID:21934132 | GFPT2 | Human | all-trans-retinoic acid | increases expression | EXP | | 6480464 | Tretinoin results in increased expression of GFPT2 mRNA | CTD | PMID:23724009 | GFPT2 | Human | ampicillin | multiple interactions | ISO | Gfpt2 (Rattus norvegicus) | 6480464 | [Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of GFPT2 protein | CTD | PMID:30545405 | GFPT2 | Human | antirheumatic drug | decreases expression | EXP | | 6480464 | Antirheumatic Agents results in decreased expression of GFPT2 mRNA | CTD | PMID:24449571 | GFPT2 | Human | arsane | affects methylation | EXP | | 6480464 | Arsenic affects the methylation of GFPT2 gene | CTD | PMID:25304211 | GFPT2 | Human | arsenic atom | affects methylation | EXP | | 6480464 | Arsenic affects the methylation of GFPT2 gene | CTD | PMID:25304211 | GFPT2 | Human | atrazine | increases expression | EXP | | 6480464 | Atrazine results in increased expression of GFPT2 mRNA | CTD | PMID:22378314 | GFPT2 | Human | Azoxymethane | multiple interactions | ISO | Gfpt2 (Mus musculus) | 6480464 | [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GFPT2 mRNA | CTD | PMID:29950665 | GFPT2 | Human | benzo[a]pyrene | increases expression | EXP | | 6480464 | Benzo(a)pyrene results in increased expression of GFPT2 mRNA | CTD | PMID:20064835 and PMID:32234424 | GFPT2 | Human | benzo[a]pyrene | affects methylation | EXP | | 6480464 | Benzo(a)pyrene affects the methylation of GFPT2 3' UTR and Benzo(a)pyrene affects the methylation of GFPT2 promoter | CTD | PMID:27901495 | GFPT2 | Human | benzo[a]pyrene | increases methylation | EXP | | 6480464 | Benzo(a)pyrene results in increased methylation of GFPT2 exon | CTD | PMID:27901495 | GFPT2 | Human | bisphenol A | affects expression | ISO | Gfpt2 (Rattus norvegicus) | 6480464 | bisphenol A affects the expression of GFPT2 mRNA | CTD | PMID:25181051 | GFPT2 | Human | bisphenol A | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with Fulvestrant] results in decreased methylation of GFPT2 gene | CTD | PMID:31601247 | GFPT2 | Human | bisphenol A | decreases methylation | EXP | | 6480464 | bisphenol A results in decreased methylation of GFPT2 gene | CTD | PMID:31601247 | GFPT2 | Human | bisphenol A | decreases expression | ISO | Gfpt2 (Rattus norvegicus) | 6480464 | bisphenol A results in decreased expression of GFPT2 mRNA | CTD | PMID:34947998 | GFPT2 | Human | bisphenol A | increases expression | ISO | Gfpt2 (Mus musculus) | 6480464 | bisphenol A results in increased expression of GFPT2 mRNA | CTD | PMID:30951980 | GFPT2 | Human | bisphenol A | decreases expression | ISO | Gfpt2 (Mus musculus) | 6480464 | bisphenol A results in decreased expression of GFPT2 mRNA | CTD | PMID:25594700 and PMID:38074096 | GFPT2 | Human | bisphenol F | multiple interactions | EXP | | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of GFPT2 mRNA | CTD | PMID:28628672 | GFPT2 | Human | bisphenol F | increases expression | ISO | Gfpt2 (Mus musculus) | 6480464 | bisphenol F results in increased expression of GFPT2 mRNA | CTD | PMID:30951980 | GFPT2 | Human | butanal | increases expression | EXP | | 6480464 | butyraldehyde results in increased expression of GFPT2 mRNA | CTD | PMID:26079696 | GFPT2 | Human | cadmium dichloride | increases expression | ISO | Gfpt2 (Rattus norvegicus) | 6480464 | Cadmium Chloride results in increased expression of GFPT2 mRNA | CTD | PMID:33453195 | GFPT2 | Human | cadmium dichloride | decreases expression | EXP | | 6480464 | Cadmium Chloride results in decreased expression of GFPT2 mRNA | CTD | PMID:38568856 | GFPT2 | Human | calcitriol | decreases expression | EXP | | 6480464 | Calcitriol results in decreased expression of GFPT2 mRNA | CTD | PMID:26485663 | GFPT2 | Human | carbamazepine | affects expression | EXP | | 6480464 | Carbamazepine affects the expression of GFPT2 mRNA | CTD | PMID:25979313 | GFPT2 | Human | carbon nanotube | increases expression | EXP | | 6480464 | Nanotubes and Carbon results in increased expression of GFPT2 mRNA | CTD | PMID:25102311 | GFPT2 | Human | carbon nanotube | increases expression | ISO | Gfpt2 (Mus musculus) | 6480464 | Nanotubes and Carbon results in increased expression of GFPT2 mRNA | CTD | PMID:25554681 | GFPT2 | Human | carbon nanotube | affects expression | ISO | Gfpt2 (Mus musculus) | 6480464 | Nanotubes and Carbon analog affects the expression of GFPT2 mRNA | CTD | PMID:25554681 | GFPT2 | Human | CGP 52608 | multiple interactions | EXP | | 6480464 | CGP 52608 promotes the reaction [RORA protein binds to GFPT2 gene] | CTD | PMID:28238834 | GFPT2 | Human | chromium(6+) | decreases expression | EXP | | 6480464 | chromium hexavalent ion results in decreased expression of GFPT2 mRNA | CTD | PMID:30690063 | GFPT2 | Human | cisplatin | decreases expression | EXP | | 6480464 | Cisplatin results in decreased expression of GFPT2 mRNA | CTD | PMID:19561079 | GFPT2 | Human | cisplatin | multiple interactions | EXP | | 6480464 | [Cisplatin co-treated with jinfukang] results in decreased expression of GFPT2 mRNA | CTD | PMID:27392435 | GFPT2 | Human | clobetasol | increases expression | ISO | Gfpt2 (Mus musculus) | 6480464 | Clobetasol results in increased expression of GFPT2 mRNA | CTD | PMID:27462272 | GFPT2 | Human | copper(II) chloride | increases expression | EXP | | 6480464 | cupric chloride results in increased expression of GFPT2 mRNA | CTD | PMID:38568856 | GFPT2 | Human | copper(II) sulfate | affects expression | EXP | | 6480464 | Copper Sulfate affects the expression of GFPT2 mRNA | CTD | PMID:19549813 | GFPT2 | Human | crocidolite asbestos | increases expression | EXP | | 6480464 | Asbestos and Crocidolite results in increased expression of GFPT2 mRNA | CTD | PMID:24160326 | GFPT2 | Human | crocidolite asbestos | decreases expression | ISO | Gfpt2 (Mus musculus) | 6480464 | Asbestos and Crocidolite results in decreased expression of GFPT2 mRNA | CTD | PMID:29279043 | GFPT2 | Human | DDE | decreases expression | EXP | | 6480464 | Dichlorodiphenyl Dichloroethylene results in decreased expression of GFPT2 mRNA | CTD | PMID:38568856 | GFPT2 | Human | dexamethasone | multiple interactions | EXP | | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of GFPT2 mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of GFPT2 mRNA | CTD | PMID:28628672 | GFPT2 | Human | dextran sulfate | multiple interactions | ISO | Gfpt2 (Mus musculus) | 6480464 | [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GFPT2 mRNA | CTD | PMID:29950665 | GFPT2 | Human | dioxygen | multiple interactions | ISO | Gfpt2 (Mus musculus) | 6480464 | [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of GFPT2 mRNA | CTD | PMID:30529165 | GFPT2 | Human | diuron | decreases expression | ISO | Gfpt2 (Rattus norvegicus) | 6480464 | Diuron results in decreased expression of GFPT2 mRNA | CTD | PMID:21551480 and PMID:25152437 | GFPT2 | Human | dorsomorphin | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | GFPT2 | Human | doxorubicin | decreases expression | EXP | | 6480464 | Doxorubicin results in decreased expression of GFPT2 mRNA | CTD | PMID:29803840 | GFPT2 | Human | endosulfan | increases expression | ISO | Gfpt2 (Rattus norvegicus) | 6480464 | Endosulfan results in increased expression of GFPT2 mRNA | CTD | PMID:29391264 | GFPT2 | Human | entinostat | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GFPT2 mRNA | CTD | PMID:27188386 | GFPT2 | Human | entinostat | increases expression | EXP | | 6480464 | entinostat results in increased expression of GFPT2 mRNA | CTD | PMID:26272509 | GFPT2 | Human | epoxiconazole | decreases expression | ISO | Gfpt2 (Mus musculus) | 6480464 | epoxiconazole results in decreased expression of GFPT2 mRNA | CTD | PMID:35436446 | GFPT2 | Human | ethanol | decreases expression | ISO | Gfpt2 (Mus musculus) | 6480464 | Ethanol results in decreased expression of GFPT2 mRNA | CTD | PMID:29018328 | GFPT2 | Human | ethanol | affects expression | ISO | Gfpt2 (Mus musculus) | 6480464 | Ethanol affects the expression of GFPT2 mRNA | CTD | PMID:30319688 | GFPT2 | Human | fulvestrant | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with Fulvestrant] results in decreased methylation of GFPT2 gene | CTD | PMID:31601247 | GFPT2 | Human | furan | decreases expression | ISO | Gfpt2 (Rattus norvegicus) | 6480464 | furan results in decreased expression of GFPT2 mRNA | CTD | PMID:25539665 | GFPT2 | Human | gentamycin | multiple interactions | ISO | Gfpt2 (Rattus norvegicus) | 6480464 | [Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of GFPT2 protein | CTD | PMID:30545405 | GFPT2 | Human | gentamycin | increases expression | ISO | Gfpt2 (Rattus norvegicus) | 6480464 | Gentamicins results in increased expression of GFPT2 mRNA | CTD | PMID:33387578 | GFPT2 | Human | Indeno[1,2,3-cd]pyrene | decreases expression | ISO | Gfpt2 (Mus musculus) | 6480464 | indeno(1 more ... | CTD | PMID:26377693 | GFPT2 | Human | indometacin | multiple interactions | EXP | | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of GFPT2 mRNA and [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in decreased expression of GFPT2 mRNA | CTD | PMID:28628672 | GFPT2 | Human | isoprenaline | increases expression | ISO | Gfpt2 (Mus musculus) | 6480464 | Isoproterenol results in increased expression of GFPT2 mRNA | CTD | PMID:20003209 | GFPT2 | Human | ketamine | decreases expression | ISO | Gfpt2 (Rattus norvegicus) | 6480464 | Ketamine results in decreased expression of GFPT2 mRNA | CTD | PMID:20080153 | GFPT2 | Human | Licochalcone B | increases expression | EXP | | 6480464 | licochalcone B results in increased expression of GFPT2 mRNA | CTD | PMID:33647349 | GFPT2 | Human | lipopolysaccharide | multiple interactions | EXP | | 6480464 | [S-(1 more ... | CTD | PMID:35811015 | GFPT2 | Human | lipopolysaccharide | increases expression | EXP | | 6480464 | Lipopolysaccharides results in increased expression of GFPT2 mRNA | CTD | PMID:35811015 | GFPT2 | Human | methylparaben | decreases expression | EXP | | 6480464 | methylparaben results in decreased expression of GFPT2 mRNA | CTD | PMID:31745603 | GFPT2 | Human | metronidazole | multiple interactions | ISO | Gfpt2 (Rattus norvegicus) | 6480464 | [Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of GFPT2 protein | CTD | PMID:30545405 | GFPT2 | Human | N-methyl-4-phenylpyridinium | increases expression | EXP | | 6480464 | 1-Methyl-4-phenylpyridinium results in increased expression of GFPT2 mRNA | CTD | PMID:24810058 | GFPT2 | Human | neomycin | multiple interactions | ISO | Gfpt2 (Rattus norvegicus) | 6480464 | [Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of GFPT2 protein | CTD | PMID:30545405 | GFPT2 | Human | nickel atom | increases expression | EXP | | 6480464 | Nickel results in increased expression of GFPT2 mRNA | CTD | PMID:24768652 and PMID:25583101 | GFPT2 | Human | nickel sulfate | increases expression | EXP | | 6480464 | nickel sulfate results in increased expression of GFPT2 mRNA | CTD | PMID:22714537 | GFPT2 | Human | O-methyleugenol | increases expression | EXP | | 6480464 | methyleugenol results in increased expression of GFPT2 mRNA | CTD | PMID:32234424 | GFPT2 | Human | ozone | increases expression | EXP | | 6480464 | Ozone results in increased expression of GFPT2 mRNA | CTD | PMID:23033980 | GFPT2 | Human | ozone | multiple interactions | ISO | Gfpt2 (Mus musculus) | 6480464 | [Air Pollutants results in increased abundance of Ozone] which results in decreased expression of GFPT2 mRNA | CTD | PMID:34911549 | GFPT2 | Human | paraquat | increases expression | ISO | Gfpt2 (Rattus norvegicus) | 6480464 | Paraquat results in increased expression of GFPT2 mRNA | CTD | PMID:32680482 | GFPT2 | Human | perfluorohexanesulfonic acid | increases expression | ISO | Gfpt2 (Mus musculus) | 6480464 | perfluorohexanesulfonic acid results in increased expression of GFPT2 mRNA | CTD | PMID:37995155 | GFPT2 | Human | perfluorooctanoic acid | increases expression | EXP | | 6480464 | perfluorooctanoic acid results in increased expression of GFPT2 mRNA | CTD | PMID:23978341 | GFPT2 | Human | phenylmercury acetate | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GFPT2 mRNA | CTD | PMID:27188386 | GFPT2 | Human | potassium chromate | multiple interactions | EXP | | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of GFPT2 mRNA | CTD | PMID:22079256 | GFPT2 | Human | potassium chromate | decreases expression | EXP | | 6480464 | potassium chromate(VI) results in decreased expression of GFPT2 mRNA | CTD | PMID:22079256 and PMID:22714537 | GFPT2 | Human | progesterone | increases expression | EXP | | 6480464 | Progesterone results in increased expression of GFPT2 mRNA | CTD | PMID:18037150 | GFPT2 | Human | rac-lactic acid | decreases expression | EXP | | 6480464 | Lactic Acid results in decreased expression of GFPT2 mRNA | CTD | PMID:30851411 | GFPT2 | Human | S-(1,2-dichlorovinyl)-L-cysteine | multiple interactions | EXP | | 6480464 | [S-(1 more ... | CTD | PMID:35811015 | GFPT2 | Human | SB 431542 | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | GFPT2 | Human | serpentine asbestos | increases expression | EXP | | 6480464 | Asbestos and Serpentine results in increased expression of GFPT2 mRNA | CTD | PMID:24160326 | GFPT2 | Human | silicon dioxide | increases expression | EXP | | 6480464 | Silicon Dioxide analog results in increased expression of GFPT2 mRNA | CTD | PMID:23806026 and PMID:25895662 | GFPT2 | Human | sodium arsenite | affects methylation | EXP | | 6480464 | sodium arsenite affects the methylation of GFPT2 gene | CTD | PMID:28589171 | GFPT2 | Human | sodium arsenite | increases expression | EXP | | 6480464 | sodium arsenite results in increased expression of GFPT2 mRNA | CTD | PMID:29301061 and PMID:38568856 | GFPT2 | Human | temozolomide | decreases expression | EXP | | 6480464 | Temozolomide results in decreased expression of GFPT2 mRNA | CTD | PMID:31758290 | GFPT2 | Human | tert-butyl hydroperoxide | increases expression | EXP | | 6480464 | tert-Butylhydroperoxide results in increased expression of GFPT2 mRNA | CTD | PMID:15336504 | GFPT2 | Human | tetrachloromethane | increases expression | ISO | Gfpt2 (Rattus norvegicus) | 6480464 | Carbon Tetrachloride results in increased expression of GFPT2 mRNA | CTD | PMID:31150632 | GFPT2 | Human | thioacetamide | increases expression | ISO | Gfpt2 (Rattus norvegicus) | 6480464 | Thioacetamide results in increased expression of GFPT2 mRNA | CTD | PMID:34492290 | GFPT2 | Human | thiram | increases expression | EXP | | 6480464 | Thiram results in increased expression of GFPT2 mRNA | CTD | PMID:38568856 | GFPT2 | Human | titanium dioxide | multiple interactions | ISO | Gfpt2 (Mus musculus) | 6480464 | [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GFPT2 mRNA | CTD | PMID:29950665 | GFPT2 | Human | titanium dioxide | decreases methylation | ISO | Gfpt2 (Mus musculus) | 6480464 | titanium dioxide results in decreased methylation of GFPT2 gene | CTD | PMID:35295148 | GFPT2 | Human | trichloroethene | increases expression | ISO | Gfpt2 (Rattus norvegicus) | 6480464 | Trichloroethylene results in increased expression of GFPT2 mRNA | CTD | PMID:33387578 | GFPT2 | Human | trichostatin A | increases expression | EXP | | 6480464 | trichostatin A results in increased expression of GFPT2 mRNA | CTD | PMID:24935251 | GFPT2 | Human | triptonide | increases expression | ISO | Gfpt2 (Mus musculus) | 6480464 | triptonide results in increased expression of GFPT2 mRNA | CTD | PMID:33045310 | GFPT2 | Human | troglitazone | increases expression | EXP | | 6480464 | troglitazone results in increased expression of GFPT2 mRNA | CTD | PMID:19140230 | GFPT2 | Human | urethane | increases expression | EXP | | 6480464 | Urethane results in increased expression of GFPT2 mRNA | CTD | PMID:28818685 | GFPT2 | Human | valproic acid | increases expression | EXP | | 6480464 | Valproic Acid results in increased expression of GFPT2 mRNA | CTD | PMID:19101580 more ... | GFPT2 | Human | valproic acid | affects expression | EXP | | 6480464 | Valproic Acid affects the expression of GFPT2 mRNA | CTD | PMID:25979313 | GFPT2 | Human | valproic acid | increases methylation | EXP | | 6480464 | Valproic Acid results in increased methylation of GFPT2 gene | CTD | PMID:29154799 | GFPT2 | Human | vancomycin | multiple interactions | ISO | Gfpt2 (Rattus norvegicus) | 6480464 | [Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of GFPT2 protein | CTD | PMID:30545405 | GFPT2 | Human | zinc atom | multiple interactions | EXP | | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of GFPT2 mRNA | CTD | PMID:18593933 | GFPT2 | Human | zinc(0) | multiple interactions | EXP | | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of GFPT2 mRNA | CTD | PMID:18593933 | |